mRNA-based cancer therapeutics

Abstract

Due to the fact that mRNA technology allows the production of diverse vaccines and treatments in a shorter time frame and with reduced expense compared to conventional approaches, there has been a surge in the use of mRNA-based therapeutics in recent years. With the aim of encoding tumour antigens for cancer vaccines, cytokines for immunotherapy, tumour suppressors to inhibit tumour development, chimeric antigen receptors for engineered T cell therapy or genomeediting proteins for gene therapy, many of these therapeutics have shown promising efcacy in preclinical studies, and some have even entered clinical trials. Given the evidence supporting the efectiveness and safety of clinically approved mRNA vaccines, coupled with growing interest in mRNA-based therapeutics, mRNA technology is poised to become one of the major pillars in cancer drug development. In this Review, we present in vitro transcribed mRNA-based therapeutics for cancer treatment, including the characteristics of the various types of synthetic mRNA, the packaging systems for efcient mRNA delivery, preclinical and clinical studies, current challenges and future prospects in the feld. We anticipate the translation of promising mRNA-based treatments into clinical applications, to ultimately beneft patients.